SciMatic
Journals
Thesis Rep
Docs
Products
SciMatic.net
Journament
Journal Manager
Subjects
Thesis
ImProofer
Research Groups
Letter Pad
Conferences
Services
About
SciMatic
Blog
Team
Earn With Us
Join Us
Contact Us
EN
English
Türkçe
Español
Português
Pусский
Filipino
Tiếng Việt
हिन्दी
العربية
বাংলা
Deutsch
中文
Login
Keyword Connections
targeted therapy
Journals
12
1
Scientific reports
2
Physical chemistry chemical physics : PCCP
3
nanomedicine (london, england)
4
artificial cells, nanomedicine, and biotechnology
5
the journal of pathology
6
digestive and liver disease : official journal of the italian society of gastroenterology and the italian association for the study of the liver
7
thyroid : official journal of the american thyroid association
8
acta medica academica
9
lung cancer (amsterdam, netherlands)
10
Photodiagnosis and photodynamic therapy
11
molecular therapy oncolytics
12
Lung Cancer (Auckland, N.Z.)
Research Groups
0
No Research Group Connected
Bibliographies
30
1
Hypericin and its radio iodinated derivatives - a novel combined approach for the treatment of pediatric alveolar rhabdomyosarcoma cells in vitro.
2
and MD Simulation Study to Explore Physicochemical Parameters for Antibacterial Peptide to Become Potent Anticancer Peptide.
3
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
4
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
5
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
6
targeting hypoxia inducible factors-1α as a novel therapy in fibrosis
7
adenosquamous carcinoma of the lung
8
current strategies and future perspectives for precision medicine in pancreatic cancer
9
editorial: update on the treatment of metastatic non-small cell lung cancer (nsclc) in new era of personalised medicine
10
surgical management of advanced and metastatic renal cell carcinoma: a multidisciplinary approach
11
use of a combination of Аvastin and low-dose interferon- α in the first-line treatment of metastatic renal-cell cancer
12
nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments
13
an expression of concern on discoidin domain receptors: potential actors and targets in cancer
14
current idea of an algorithm for drug treatment and optimal succession of using targeted drugs
15
emerging treatments for her2-positive early-stage breast cancer: focus on neratinib
16
the tip of the iceberg: clinical implications of genomic sequencing projects in head and neck cancer
17
systemic therapy of cancer: facts and expectations
18
targeted and effective photodynamic therapy for cancer using functionalized nanomaterials
19
molecular differences in the kras gene mutation between a primary tumor and related metastatic sites – case report and a literature review
20
omics and immunologic approaches to optimizing cure rates in her2-positive breast carcinomas.
21
analysis of the efficacy and survival of third-line treatment in advanced non-small cell lung cancer
22
first-line treatment in egfr mutant non-small cell lung cancer: is there a best option?
23
hepatocellular carcinoma: past and future of molecular target therapy
24
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the Gene Have Durable Responses to ALK Kinase Inhibitors.
25
Enrichment experiment of ventilation air methane (0.5%) by the mechanical tower.
26
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
27
SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review.
28
Mechanistic Insights and Therapeutic Potentials of Ubiquitin-Proteasome System in Non-Small Cell Lung Cancer.
29
Targeted antineoplastic therapy in critically ill cancer patients: a multicenter analysis of the iCHOP registry.
30
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma.
×
SciMatic on Your Phone
Track your articles, view certificates, and stay updated — anywhere, anytime.
Google Play